New Slow-Release olanzapine shots aim to simplify schizophrenia treatment

NCT ID NCT06319170

Completed Disease control Sponsor: Teva Branded Pharmaceutical Products R&D LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 trial tested three different slow-release versions of the schizophrenia drug olanzapine in 106 adults with schizophrenia or schizoaffective disorder. The goal was to see how the body absorbs and processes each version compared to the standard immediate-release injection. Researchers also monitored safety and side effects over 28 days after a single shot.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: olanzapine (extended-release injection)
What this could lead to: If successful, this could lead to a longer-acting version of olanzapine that requires less frequent injections, making it easier for people with schizophrenia to stay on treatment.
What could go wrong: This is an early Phase 1 study focused on drug levels in the body, not on how well the drug works. The new formulations may not prove safer or more effective than the current version.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOAFFECTIVE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Psychotic Disorders schizoaffective disorder schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA / SCHIZOAFFECTIVE DISORDER

Contacts and locations

Locations

Teva Investigational Site 15726

Marlton, New Jersey, 08053, United States
Teva Investigational Site 15727

Hollywood, Florida, 33024, United States
Teva Investigational Site 15728

Decatur, Georgia, 30030, United States
Teva Investigational Site 15729

Atlanta, Georgia, 30331, United States
Teva Investigational Site 15730

Los Alamitos, California, 90720, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.